Jeffrey Winters - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Jeffrey Winters's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Jeffrey Winters
Verified
Editor-in-Chief, Mechanical Engineering Magazine
New York
Beats
Technology Telecoms Enterprise Tech Media AI
None!
Content
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial - Nature Communications
By Jacob J. Orme, Robert McWilliams, Robert Mcwilliams Verified, Matthew Block, Aaron Mansfield, Svetomir N. Markovic, Haidong Dong, Fabrice Lucien, Jeffrey Winters Verified| Nature Verified AbstractImmune checkpoint inhibitors (ICI) are effective for advanced melanoma. However, most develop ICI resistance. Tumor-derived soluble PD-L1 (sPD-L1) and other immunosuppressive factors drive resistance. We hypothesized that therapeutic plasma exchange (TPE) may remove sPD-L1 from circulation and overcome ICI resistance. Patients with metastatic ICI-resistant melanoma and elevated sPD-L1 received radiotherapy to a minority of metastatic lesions, TPE, and ICI re-challenge.
Legendary Case of Factitious Disorder Presenting as ‘Sickle Cell Disease’ Creates Challenges for All Medical Specialties
By Olivia Iverson Verified, Theresa N. Kinard, Jeffrey Winters Verified, Lance Williams, lANCE Williams| Wiley Online Library Verified Please review our Terms and Conditions of Use and check box below to share full-text version of article. I have read and accept the Wiley Online Library Terms and Conditions of UseUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial - Nature Communications
By Jacob J. Orme, Robert McWilliams, Robert Mcwilliams Verified, Matthew Block, Aaron Mansfield, Svetomir N. Markovic, Haidong Dong, Fabrice Lucien, Jeffrey Winters Verified| Nature Verified AbstractImmune checkpoint inhibitors (ICI) are effective for advanced melanoma. However, most develop ICI resistance. Tumor-derived soluble PD-L1 (sPD-L1) and other immunosuppressive factors drive resistance. We hypothesized that therapeutic plasma exchange (TPE) may remove sPD-L1 from circulation and overcome ICI resistance. Patients with metastatic ICI-resistant melanoma and elevated sPD-L1 received radiotherapy to a minority of metastatic lesions, TPE, and ICI re-challenge.
Company Info
Mechanical Engineering Magazine
New York, New York, United States
+1 800-843-2763